Healthcare · Biotechnology · Market cap $1.6B · $110.47 · 52-week range $26.19–$155.29
Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-09-08 | Kayyem Jon Faiz | director | 5,000 | $113.52 | $567,580 | SEC Form 4 |
| 2026-09-08 | FORSYTH DOUGLAS | director | 2,500 | $114.65 | $286,617 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 9,681 | $112.28 | $1,087,001 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 1,219 | $111.88 | $136,382 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 500 | $108.23 | $54,118 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 1,100 | $107.12 | $117,836 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 6,605 | $100.64 | $664,719 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 5,895 | $99.29 | $585,343 | SEC Form 4 |
Last updated September 15, 2026.
ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.